- Featured Product
- KD/KO Validated
C5aR Polyclonal antibody
C5aR Polyclonal Antibody for WB, IHC, IF/ICC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (1)
Applications
WB, IHC, IF/ICC, ELISA and More (1)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
| Positive WB detected in | L02 cells, PC-3 cells, U-937 cells |
| Positive IHC detected in | human tonsillitis tissue, human lung tissue, human liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Planning an IHC experiment? We recommend our IHCeasy C5AR1 Ready-To-Use IHC Kit. C5AR1 primary antibody included.
Planning an IF experiment? We recommend our CoraLite® Plus 488 conjugated versions of this antibody.
推荐稀释比
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:3000 |
| Immunohistochemistry (IHC) | IHC : 1:200-1:800 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
21316-1-AP targets C5aR in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Applications | WB, IHC, IF/ICC, ELISA Application Description |
| Cited Applications | WB, IHC, IF |
| Tested Reactivity | human |
| Cited Reactivity | human, pig |
| Immunogen | C5aR fusion protein Ag15968 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | complement component 5a receptor 1 |
| Synonyms | C5A, C5a R, C5aR, C5AR1, C5R1, CD88 |
| Calculated Molecular Weight | 350 aa, 39 kDa |
| Observed Molecular Weight | 45 kDa |
| GenBank Accession Number | BC008982 |
| Gene Symbol | C5aR |
| Gene ID (NCBI) | 728 |
| RRID | AB_10733105 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P21730 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
C5aR, also named as CD88, is a G protein-coupled receptor for the anaphylatoxin C5a, a cleavage product of the complement cascade. The C5a ligand is a proinflammatory component of host defense. C5aR is activated upon binding of the C5a molecule. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The deduced sequence of C5aR contains 350 amino acids, giving a calculated molecular weight of 39 kDa. C5aR has an N-linked glycosylation site in the N-terminal extracellular domain. The apparent molecular weight of C5aR is about 40-52 kDa (PMID: 1847994; 9136907; 9136907; 2007135).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for C5aR antibody 21316-1-AP | Download protocol |
| IHC protocol for C5aR antibody 21316-1-AP | Download protocol |
| IF protocol for C5aR antibody 21316-1-AP | Download protocol |
| FC protocol for C5aR antibody 21316-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Immunity Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. | ||
Theranostics The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition. | ||
Sci Rep Nerve Growth Factor Secretion From Pulp Fibroblasts is Modulated by Complement C5a Receptor and Implied in Neurite Outgrowth. | ||
Sci Rep Cardiac Depression in Pigs after Multiple Trauma - Characterization of Posttraumatic Structural and Functional Alterations. | ||
Cell Signal The C5aR1 complement receptor: A novel immunomodulator of insulin action in skeletal muscle
| ||
Front Immunol Complement Activation and Organ Damage After Trauma-Differential Immune Response Based on Surgical Treatment Strategy. |
